AI Stock Market News Today

CEO Charles Lacey Compton III sold approximately $720,000 in Fastly shares through pre-planned and tax-related transactions. The sales represent a small fraction of his total holdings and do not indicate a discretionary shift in sentiment.

• Total sale value of ~$720,000
• Majority of sales were pre-scheduled via 10b5-1 plan

Amazon is integrating One Medical and Amazon Pharmacy to offer a comprehensive weight loss service centered on GLP-1 medications. The initiative leverages the company's logistics network to provide streamlined access to high-demand obesity treatments.

• New weight management program integrates One Medical and Amazon Pharmacy
• Provides access to popular GLP-1 drugs including Foundayo and oral Wegovy

Investors are weighing explosive AI-driven cloud growth against rising capital expenditures and intense competition. The software giant is scheduled to report its fiscal third-quarter results after the market closes on April 29.

• Fiscal Q3 earnings report scheduled for April 29
• Azure and other cloud services grew 39% in the previous quarter

Bill Ackman has heavily weighted his hedge fund's holdings toward Alphabet, Amazon, and Meta Platforms. The strategy emphasizes long-term value and vertical integration within the artificial intelligence sector.

• 38% portfolio concentration in GOOGL, AMZN, and META
• Emphasis on custom silicon (TPUs, Trainium, Inferentia)

While Nvidia remains the dominant force in AI hardware, analysts suggest that custom chipmakers and key rivals may see higher growth rates through 2028. Broadcom, AMD, and Marvell are positioned to capture market share as hyperscalers seek cost-effective, tailored alternatives.

• Nvidia's projected 26.2% CAGR is lower than key rivals
• Broadcom leads growth projections at 35.6% CAGR

Animal health leader Zoetis is trading at its lowest P/E ratio ever following setbacks with its Librela pain treatment. Despite the volatility, strong pipeline prospects and demographic tailwinds suggest a recovery.

• P/E ratio dropped to 19x from a 39x historical average
• Librela sales fell 16% in 2025 due to safety concerns